Skip to main content

Moderna, Inc.

BiotechnologyFounded 2010
Reviewed by Swet Parvadiya
Company data updated: October 2026

Leadership History

Moderna: CEO History

3 leaders · 2010 to present

Who is the CEO of Moderna?

Stéphane Bancel is the CEO of Moderna, in the role since 2011.

Current CEO
Stéphane Bancel (since 2011)
Leaders documented
4
Founded
2010
NameRoleFromToYears in role
Stephen HogePresident2012Present14
Stéphane BancelChief Executive Officer (first CEO)2011Present15
Noubar AfeyanCo-Founder & Chairman2010Present16

Company Overview

Moderna, Inc. is a Nasdaq-listed biotechnology company headquartered in Cambridge, Massachusetts. It develops medicines that deliver mRNA instructions into cells so the body produces a target protein, such as a viral antigen or tumor neoantigen. As of 2026 it markets COVID-19 vaccines (Spikevax, mNEXSPIKE), an RSV vaccine (mRESVIA) and a flu vaccine (mFLUSIVA), and co-develops the individualized cancer therapy intismeran autogene with Merck.

Stephen Hoge

President

2012 – Present

14 years (current)

Key Decisions & Impact

Joined Moderna in late 2012 from McKinsey & Company to lead R&D strategy, pivoted research from rare monogenic diseases toward infectious disease vaccines in 2018, directed clinical design for mRNA-1273 (Spikevax) in January 2020, and expanded mRNA applications into individualized neoantigen cancer therapies in partnership with Merck.

Legacy

Serves as President directing preclinical research, clinical development, and platform innovation, leading the advancement of Moderna's pipeline from an early research concept into five commercialized vaccines and multiple late-stage Phase 3 oncology candidates.

Stéphane Bancel

Chief Executive Officer (first CEO)

2011 – Present

15 years (current)

Key Decisions & Impact

Committed Moderna to an integrated platform model, pivoted it toward vaccines before 2020, led the COVID-19 vaccine program, and steered the 2024-2026 cost cuts and refocus on respiratory and oncology products.

Legacy

Bancel has led Moderna from a pre-revenue startup to a $180 billion market cap at its peak, overseeing the development of Spikevax in record time and the company's transition to a multi-product biotechnology enterprise. He oversaw about $2.2 billion of operating cost cuts in 2025 and a cash-breakeven target of 2028. In November 2024 he gave up direct oversight of sales and stayed on as chief executive (Bloomberg, November 5, 2024). Bancel joined Moderna in March 2011 as its second employee and a board member, and was appointed Chief Executive Officer in October 2011, making him the company's first CEO; Moderna was founded in 2010 without a prior chief executive. He came from bioMérieux, the French diagnostics company, where he had been CEO for five years, and before that held manufacturing and country-management roles at Eli Lilly.

Noubar Afeyan

Co-Founder & Chairman

2010 – Present

16 years (current)

Key Decisions & Impact

Co-founded Moderna in 2010 via his venture creation firm Flagship Pioneering, recruited Stéphane Bancel as CEO in 2011, assembled the initial scientific advisory board alongside Robert Langer, and guided the company through its December 2018 record biotech initial public offering raising $604 million.

Legacy

Has served as Chairman of the Board of Directors since inception, providing venture financing, governance, and long-term capital strategy that helped build Moderna from a startup laboratory into a public biotechnology enterprise.

Other senior executives

These officers report to the chief executive and are not part of the CEO timeline above.

  • Jamey Mock, Chief Financial Officer (2022 – present)Appointed CFO in August 2022 after serving as CFO of PerkinElmer and spending 14 years in financial leadership at General Electric. Directed operational spending reductions that lowered annual expenses by $2.2 billion in 2025, streamlined manufacturing footprints, and set capital allocation targets aimed at reaching operational cash breakeven by 2028.Source →

Challenges & Strategic Context

Moderna's core challenge is cash: revenue fell from $19.3 billion in 2022 to $1.94 billion in 2025, and cash and investments dropped from $8.1 billion at end-2025 to $6.9 billion by June 30, 2026, with year-end 2026 guidance of $4.7-5.2 billion. New launches (mFLUSIVA) and the cancer vaccine must scale before that cushion runs thin.

Moderna CEO and Leadership FAQ

Who is Stéphane Bancel and what was his leadership role in scaling Moderna?

Stéphane Bancel is a French business executive and biochemical engineer who joined Moderna as CEO in 2011. Bancel built Moderna from a 3-person startup into a $100B+ market cap leader during the pandemic, raising over $2.0 billion in pre-IPO private capital, leading the record 2018 IPO, and mobilizing Operation Warp Speed.

Who is Noubar Afeyan and what is his role as Co-Founder and Chairman?

Dr. Noubar Afeyan is an American entrepreneur, biochemical engineer, and venture capitalist who co-founded Moderna in 2010 and has served as Chairman of the Board of Directors since inception. Afeyan is the founder and CEO of Flagship Pioneering, which created and funded Moderna within its life-sciences incubator.

Who was Dr. Stephen Hoge and what is his impact as President of Moderna?

Dr. Stephen Hoge, a physician and former McKinsey partner, joined Moderna in 2012 and serves as President. Hoge oversees research and development, clinical therapeutics pipelines, regulatory interactions with the FDA, and platform technology innovation.

How did Stéphane Bancel lead the historic 48-hour design of the COVID-19 vaccine in 2020?

On January 11, 2020, when Chinese health authorities released the genetic sequence of SARS-CoV-2, Bancel and Moderna's scientific team finalized the sequence for mRNA-1273 in just 48 hours, shipping the first clinical trial batch to the US National Institutes of Health (NIH) in 42 days.

What is Stéphane Bancel's management style of 'Mindsets' and extreme urgency?

Bancel established Moderna's corporate culture around 12 core 'Mindsets', including 'We act with urgency,' 'We push past possible,' 'We pivot fearlessly,' and 'We digitize everything', demanding operational execution, scientific rigor, and rapid decision-making.

Who is Jamey Mock and what is his role as Chief Financial Officer?

Jamey Mock serves as Chief Financial Officer of Moderna, having joined from PerkinElmer. Mock manages Moderna's multi-billion-dollar capital allocation, treasury reserves, international commercial financial operations, and long-term path to sustainable profitability.

How did Stéphane Bancel manage global manufacturing scaling during the pandemic?

Faced with manufacturing 1 billion vaccine doses having previously produced only small clinical trial batches, Bancel partnered with Swiss contract manufacturer Lonza, secured emergency federal funding from BARDA, and built out dedicated global supply chains in under 9 months.

What is Stéphane Bancel's long-term vision for mRNA therapeutics by 2030?

Bancel envisions Moderna having launched dozens of commercial products by 2030, fundamentally curing multiple rare genetic childhood diseases, eliminating major respiratory infections through annual pan-respiratory shots, and turning cancer into a manageable chronic condition via personalized vaccines.

Is Stéphane Bancel still the CEO of Moderna?

Yes. Stéphane Bancel has been Moderna's CEO since October 2011 and continued in the role through 2026, including on the Q2 2026 earnings call.

Who was the first CEO of Moderna?

Stéphane Bancel was Moderna's first Chief Executive Officer. He joined in March 2011 as the company's second employee and a board member, and was appointed CEO in October 2011. Moderna was founded in 2010 and had no chief executive before him.

What is Moderna CEO Stéphane Bancel's status, and did he depart in 2024 or 2025?

Stéphane Bancel did not depart Moderna in 2024 and remains the Chief Executive Officer. Rumors of a potential departure arose following the resignation of Chief Commercial Officer Arpa Garay in late 2023, after which Bancel took direct operational control of global sales and commercial organization throughout 2024. In late 2024, Moderna restructured its executive leadership to install dedicated regional commercial presidents, allowing Bancel to concentrate on overarching corporate strategy, $2.2 billion in cost reductions, and Phase 3 clinical pipeline readouts including the mFLUSIVA flu vaccine and Merck cancer vaccine. He did not leave in 2025 either: Moderna's Form 8-K dated September 30, 2026 states that its newly appointed Chief Operating Officer, Juan Andres, will report to Chief Executive Officer Stéphane Bancel.

Who is Stéphane Bancel and what defines his leadership style?

Stéphane Bancel has served as Moderna's CEO since October 2011. Formerly the CEO of French diagnostics leader bioMérieux, Bancel is renowned for his demanding, engineering-driven management philosophy, structured milestones, and rapid decision-making. He led Moderna through its stealth phase, its record 2018 IPO, and the unprecedented global logistics mobilization of Spikevax during COVID-19.

Related Companies

Compare Moderna, Inc. Leadership With Competitors

Related Leadership Timelines

Compare executive leadership tenures and strategic transitions

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.